Ji, Changyi
Li, Yao
Kittredge, Alec
Hopiavuori, Austin
Ward, Nancy
Yao, Peng
Fukuda, Yohta
Zhang, Yu
Tsang, Stephen H.
Yang, Tingting
Funding for this research was provided by:
Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY025290)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM127652)
Article History
Received: 24 June 2019
Accepted: 19 November 2019
First Online: 13 December 2019
Competing interests
: The authors declare competing interests in relation to the work described: Provisional patent application. Patent applicant (whether author or institution): University of Rochester and Columbia University. Name of inventor(s): Tingting Yang, Stephen H. Tsang and Yu Zhang. Application number: Provisional Patent Application No. 62/785,739 and No. 62/833,069. Status of application: Provisional patent application. Specific aspect of manuscript covered in patent application: Gene therapy for BEST1 dominant mutations, including all the six mutations in the manuscript.